Fiscal Q3 net loss widened to $5.4 million, or $0.60 a share, from a $1.7 million loss, or $0.25 a share.
Operating expenses climbed to $5.5 million from $1.9 million, led by research and development rising to $4 million from $939,067.
Cash and cash equivalents totaled $10.3 million, leaving working capital of $6.9 million at June 30, 2026.
Clinical program updates for EB06 and paridiprubart
Preparations finished for a Phase 2 EB06 vitiligo study; site activation began post-quarter, with Canada recruitment expected in coming weeks.
Exploratory ARDS analyses in patients with acute kidney injury linked paridiprubart to significant mortality reductions, with MAKE30 endpoint improvements.
EDSA•
